GOVX B11
Alternative Names: DNA/MVA; DNA/MVA-unadjuvanted-vaccine; GEO-D02 DNA vaccine; GEO-D03 DNA vaccine; GeoVax Clade B DNA/MVA HIV/AIDS Vaccine; GeoVax-Clade-B-DNA/MVA-HIV/AIDS-… See moreLatest Information Update: 19 Feb 2024
At a glance
- Originator GeoVax Labs; National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 13 Feb 2024 GeoVax Labs receives patent protection for Multivalent HIV Vaccine Boost Compositions and Methods of Use
- 05 Oct 2023 GeoVax Labs receives a Notice of Allowance for Multivalent HIV Vaccine Boost Compositions and Methods of Use
- 22 Apr 2022 GOVX B11 is available for licensing as of 22 Apr 2022. www.geovax.com